Answer First
Semaglutide is a mono-agonist that targets the GLP-1 receptor only. Tirzepatide is a dual agonist, activating both the GLP-1 receptor and the GIP receptor. Retatrutide is a triple agonist, activating GLP-1, GIP, and glucagon (GCG) receptors. Each represents a progressively broader receptor engagement profile in the published literature, and each is studied as a distinct compound — not as interchangeable variants of the same mechanism.
Receptor targets: the core distinction
The single most important difference between these three peptides is which receptors they engage. Researchers use this table as a quick reference when designing comparative protocols.
| Receptor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1R (glucagon-like peptide-1 receptor) | Agonist | Agonist | Agonist |
| GIP-R (glucose-dependent insulinotropic polypeptide receptor) | Not targeted | Agonist | Agonist |
| GCG-R (glucagon receptor) | Not targeted | Not targeted | Agonist |
| Receptor count | 1 (mono-agonist) | 2 (dual agonist) | 3 (triple agonist) |
This receptor progression is why the three compounds are often studied as a class series rather than as substitutes for one another. Adding GIP receptor activity in tirzepatide, and then glucagon receptor activity in retatrutide, changes the downstream signaling pathways being investigated — not just the magnitude of a single pathway.
Pharmacokinetics: half-life, dosing, and molecular profile
All three are long-acting analogs engineered for infrequent dosing in research protocols, achieved through amino acid substitutions and, in most formulations, a fatty acid or fatty diacid moiety that promotes albumin binding and slows clearance.
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Reported half-life | ~7 days | ~5 days | ~6 days |
| Typical research dosing frequency | Weekly | Weekly | Weekly |
| Approximate molecular weight | 4,113.6 g/mol | 4,813.5 g/mol | 4,731.4 g/mol |
| Sequence backbone origin | Modified native GLP-1 (37 amino acids) | Engineered dual-receptor peptide (39 amino acids) | Engineered triple-receptor peptide (39 amino acids) |
| Year first characterized in literature | ~2012 | ~2013 | ~2020 |
The half-life differences are modest across the class — all three fall in a range compatible with once-weekly research administration schedules. Reported half-life figures vary somewhat between studies depending on formulation, assay method, and study population, so any single number should be treated as an approximation rather than a fixed constant.
Where each compound sits in the research literature
Published research on each compound clusters around different focus areas, reflecting both their receptor profile and their relative time in the literature.
- Semaglutide has the deepest and longest-running body of literature of the three, with published research spanning GLP-1 receptor signaling, appetite-regulation pathways, and metabolic markers in preclinical and clinical models.
- Tirzepatide literature focuses heavily on comparative dual-agonism, examining how combined GLP-1/GIP receptor activity differs from GLP-1 mono-agonism in metabolic and body-composition research endpoints.
- Retatrutide is the newest compound in this comparison, and its literature is smaller but growing quickly, with early published trials concentrating on triple-agonist receptor pharmacology and dose-ranging characterization.
Researchers selecting between these compounds for a given protocol should match the choice to receptor targets, not to assumptions about relative potency carried over from mainstream reporting.
Reconstitution and handling notes
All three compounds ship as lyophilized powder and follow the same general handling principles used across the GLP-1 class in research settings.
Standard reconstitution protocol (applies to all three)
- Reconstitute with bacteriostatic water, not plain sterile water, to preserve stability across multiple draws.
- Add water slowly, along the vial wall — direct streams onto lyophilized powder can denature the peptide.
- Do not shake. Gently swirl or roll the vial until the powder is fully dissolved.
- Refrigerate at 2–8°C immediately after reconstitution.
- Use within the documented stability window for the specific batch — check the COA and any supplier-provided stability data.
- Protect from light during storage; use amber or foil-wrapped vials where possible.
- Label the vial with reconstitution date and concentration to maintain protocol traceability.
Side-by-side summary
| Factor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism class | GLP-1 mono-agonist | GLP-1/GIP dual agonist | GLP-1/GIP/GCG triple agonist |
| Literature depth | Extensive | Substantial, growing | Emerging |
| Research dosing frequency | Weekly | Weekly | Weekly |
| Common research focus | Metabolic signaling, appetite pathways | Comparative dual-receptor effects | Triple-receptor pharmacology, dose-ranging |
| Available at Sequence Labs | Yes — product page | Yes — product page | Yes — product page |
Frequently asked questions
What's the difference in receptor activity between semaglutide, tirzepatide, and retatrutide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide activates GLP-1, GIP, and glucagon receptors. This receptor count is the primary pharmacological distinction between the three compounds.
Which has the longest half-life?
Semaglutide is generally reported with the longest half-life of the three, at approximately 7 days, compared to roughly 5 days for tirzepatide and 6 days for retatrutide. All three support weekly dosing schedules in research protocols.
Which compound is most-studied?
Semaglutide has the largest and longest-running published literature base of the three, having been characterized earliest. Tirzepatide's literature is substantial and expanding. Retatrutide, the newest of the three, has a smaller but rapidly growing set of published studies.
Are they interchangeable in research protocols?
No. Each compound engages a different combination of receptors and is associated with a distinct reported pharmacological profile in the literature. Substituting one for another changes the mechanistic question under study, so protocols should specify the exact compound required and verify identity against a batch-matched COA.
What purity should I look for?
Look for a third-party Certificate of Analysis showing HPLC purity of 98% or higher, mass spectrometry confirming the expected molecular weight, and a batch number that matches the vial label and is searchable in a public COA library.